CDH1 and invasive lobular breast carcinoma: To explore the impact of these mutations on patient prognosis and survival rates, we analyzed TP53-Mutant and TP53-NonMutant samples using the cBioPortal System on databases including Breast Cancer (MSK, Cancer Cell 2018), Breast Cancer (MSK, Nature Cancer 2020), Metastatic Breast Cancer (MSK, Cancer Discovery 2022), and Non-CDH1 Invasive Lobular Carcinoma (MSK, 2023).